Many therapeutic options exist for the treatment of Pneumocystis carinii pneumonia, a
common fungal opportunistic pulmonary pathogen, but treatment is often complicated by
side effects and toxicity and, more recently, markers of drug resistance have been described.
The development of immunotherapetic modalities such as active immunization or passive
immunotherapy may play an increasing important role in the prevention and treatment of
infection. Passive immunotherapy with polyclonal anti-P. carinii reagents, such as serum or …